Vaccinations in CLL: implications for COVID-19

This is the authors' abstract. We don't add key points for this paper.

In this issue of Blood, Pleyer and colleagues report results from 2 studies assessing differences in the humoral response to 2 different vaccines in patients with chronic lymphocytic leukemia (CLL) on observation or receiving a Bruton tyrosine kinase inhibitor (BTKi).1 Their findings have immediate clinical implications and call for research preparedness as we eagerly anticipate access to vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the near future.